PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Kespion, long dependent on Samsung Electronics for most of its mobile antenna sales, is attempting a business transformation through the merger of an acne-patch subsidiary and defense diversification, having posted two consecutive quarters of profit even as listing-maintenance concerns have simultaneously come to the fore.
Both operating profit and net income turned positive in Q1 2026 and remained positive in Q2 2026.
About 96% of revenue still comes from mobile antenna products, leaving the company heavily reliant on large customers such as Samsung Electronics.
The company completed the merger with hydrocolloid acne-patch maker MBTB on July 1, 2026, diversifying into beauty and healthcare.
Amid partial capital impairment, the company carried out a par-value consolidation and a capital reduction in succession, and in August 2026 was flagged as a stock at risk of being designated a management-issue stock.
The company is seeking customer diversification by expanding its defense segment through remote-control munitions and zinc-air battery development.
Kespion was established in 1998 as a wireless communication device developer and manufacturer and listed on KOSDAQ in 2005, initially operating under the name EMW Antenna. Following a change of largest shareholder to ENS Investment in 2020, the company adopted its current name in 2022.
Its core business is LDS antennas for mobile communication, alongside short-range communication antennas such as NFC, MST and WPC and outdoor wireless communication solutions.
As of the end of the third quarter, about 96% of total revenue came from mobile antenna products, a large portion of which is supplied to Samsung Electronics.
While antennas remain the core business, the defense segment, including remote-control munitions, accounts for roughly 10% of revenue, reflecting an ongoing effort to diversify customers.
In January 2026 the company acquired 100% of hydrocolloid acne-patch maker MBTB through convertible-bond-in-kind payment, and completed the absorption merger on July 1 of the same year, expanding into consumer goods and beauty healthcare.
The largest shareholder, ENS Investment, and related-party entities were counterparties in this acquisition process, leading to interpretations that new-business expansion and listing-maintenance efforts are intertwined.
Vietnamese subsidiary Woori Tech Vietnam handles antenna module manufacturing and punching processes, and recently underwent a debt-to-equity conversion to improve its capital structure.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩9.6B | -₩1B | −10.1% |
| 2025Q3 | ₩11.5B | -₩500M | −3.9% |
| 2025Q4 | ₩12.9B | -₩13,427,145 | −0.1% |
| 2026Q1 | ₩10.6B | ₩200M | 2.2% |
| 2026Q2 | ₩10B | ₩600M | 5.7% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩55.6B | -₩3.8B | -₩10.9B | −6.8% | −70.4% | 235.0% |
| 2023 | ₩63.2B | ₩1.1B | ₩2.7B | 1.7% | 11.8% | 68.0% |
| 2024 | ₩32.6B | -₩5.4B | -₩3.9B | −16.5% | −21.9% | 98.9% |
| 2025 | ₩44.1B | -₩2.7B | -₩4.6B | −6.2% | −34.2% | 81.4% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual results have swung considerably.
After posting revenue of KRW 55.57 billion with an operating loss of KRW 3.78 billion and a net loss of KRW 10.86 billion in 2022, the company grew revenue to KRW 63.21 billion in 2023 and turned profitable with operating profit of KRW 1.07 billion and net income of KRW 2.72 billion.
However, revenue plunged to KRW 32.60 billion in 2024, and the company swung back to losses with an operating loss of KRW 5.37 billion and a net loss of KRW 3.87 billion.
In 2025 revenue recovered to KRW 44.15 billion, yet the operating loss of KRW 2.74 billion and net loss of KRW 4.58 billion showed that revenue recovery and profit improvement did not fully move together.
On a quarterly basis, the operating loss narrowed from KRW 972 million on revenue of KRW 9.59 billion in Q2 2025 to KRW 452 million on revenue of KRW 11.51 billion in Q3, and further to just KRW 13 million on revenue of KRW 12.89 billion in Q4, even as the net loss reached KRW 3.27 billion that quarter, a large divergence from the operating result that suggests a sizable one-off non-operating item.
Entering 2026, both operating profit and net income turned positive for two consecutive quarters: KRW 228 million operating profit and KRW 857 million net income on revenue of KRW 10.55 billion in Q1, followed by KRW 563 million operating profit and KRW 821 million net income on revenue of KRW 9.96 billion in Q2.
Nevertheless, summing the most recent four quarters still shows a net loss due to the large Q4 2025 shortfall, while equity attributable to owners shrank from KRW 23.06 billion in 2023 to KRW 13.41 billion in 2025, and the debt ratio rose from 68.0% in 2023 to 98.9% in 2024 before easing to 81.4% in 2025, reflecting continued volatility in the capital structure.
The smartphone antenna market is in a structural phase where negotiating power with finished-device makers is steadily weakening amid slowing global smartphone shipment growth.
In a recent media interview, Kespion's CEO stated that intensifying price competition had made the need for a business restructuring keenly felt.
Given the structure of heavy reliance on a specific major customer, earnings are highly sensitive to smartphone replacement demand and shipment cycles, which is also reflected in the large historical swings in results.
The hydrocolloid patch market the company entered as a new business, used in acne patches and wound-care patches, is projected by a global research firm to grow from about USD 570 million in 2025 to roughly USD 1.09 billion by 2035.
T&L, considered the market leader in this segment, has demonstrated commercial viability with double-digit annual growth and an operating margin of around 30% since entering the U.S. market, indicating a substantial gap versus new entrant MBTB.
In the defense segment, remote-control munitions already contribute to revenue, and zinc-air batteries are being pursued as an area of potential substitute demand in military battery markets given their lower explosion risk compared with lithium-ion cells.
Across the broader KOSDAQ market, management-issue stock designations and delisting rules for stocks below a KRW 20 billion market cap threshold or failing coin-stock requirements began taking full effect from the second half of 2026, putting many small-cap issuers under restructuring pressure.
The company has stated that MBTB's earnings contribution was delayed due to initial facility investment burdens but expects overseas sales to begin materializing within the year.
Earlier, a company representative said the sales target was for this year to remain an early stage, with next year's target at KRW 10 billion and the year after at around KRW 20 billion.
The zinc-air battery project, developed in cooperation with Korea University, has completed high- and extreme-low-temperature performance evaluations and environmental testing and is proceeding with patent filings, with the company stating it expects new revenue creation through entry into the Korean defense industry in 2027.
On listing maintenance, the CEO said the company is reviewing measures such as stock consolidation in various ways to escape coin-stock delisting requirements and is working to meet KOSDAQ market-cap requirements within the year.
However, since the new-business acquisition structure involved related-party transactions and MBTB's actual sales contribution has not yet been substantial as of the acquisition date, the timing of visible earnings impact remains fluid.
In the communications segment, the company has outlined plans to expand supply of combined long-range and short-range antenna modules into construction, industrial site, and military communications electronic equipment applications.
Going forward, the key points to watch will be the pace at which new-business revenue is actually reflected and the outcome of the company's response to listing-maintenance requirements.
Profit-based valuation metrics carry limited meaning when the most recent four quarters are summed, as the result remains a net loss, and multi-year earnings have repeatedly alternated between losses and profits.
The price-to-book ratio trades at a discount to net asset value, which appears related to the company's history of partial capital impairment and shrinking equity. There is no recent dividend payment history, making dividend-related metrics of limited reference value.
The fact that both operating profit and net income turned positive for two consecutive recent quarters can be read as a positive directional signal, but since the large net loss from the immediately preceding quarter is still embedded in the trailing four-quarter sum, the durability of this trend requires confirmation from upcoming quarterly results.
Given the recent disclosure flagging concern over management-issue stock designation amid tightened listing-maintenance requirements, listing-status risk should be weighed alongside any valuation interpretation.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Both operating profit and net income turned positive in Q1 and Q2 2026, breaking from the loss trend that had persisted through Q4 2025. While revenue scale remains around KRW 10 billion per quarter, the direction of improving profitability confirmed over two consecutive quarters is notable.
Still, the trailing four-quarter sum remains a net loss, so the continuity of this trend needs reconfirmation from upcoming quarters.
The company completed its merger with hydrocolloid acne-patch maker MBTB on July 1, 2026, expanding into consumer goods. Management has set a target of reaching KRW 10 billion in sales next year and around KRW 20 billion the year after.
As the hydrocolloid patch market is projected to expand over the next decade, this could serve as a catalyst for revenue diversification depending on execution.
The defense segment, including remote-control munitions, already accounts for roughly 10% of revenue, partially easing reliance on the communications business.
Zinc-air battery development conducted with Korea University has completed high- and extreme-low-temperature and environmental performance evaluations and is at the patent-filing stage, with the company stating it expects entry into Korea's defense industry in 2027. If defense expansion translates into actual sales, it could help reduce customer concentration.
About 96% of total revenue continues to come from mobile antenna products, largely supplied to Samsung Electronics. Management itself has acknowledged that intensifying price competition made restructuring necessary.
High dependence on a single customer and single product line remains a structural vulnerability that leaves earnings highly exposed to shifts in the finished-device maker's negotiating leverage.
Despite carrying out a par-value consolidation in early 2026 and a subsequent capital reduction amid partial capital impairment, the company was disclosed as a stock at risk of management-issue designation in August 2026.
Under the tightened delisting rules, a KOSDAQ-listed stock is designated management-issue if its market cap falls below KRW 20 billion or its price stays under KRW 1,000 for 30 consecutive trading days, and delisting proceeds if the threshold is not restored for at least 45 of the following 90 trading days.
As the market-cap threshold is set to rise further to KRW 30 billion from January 2027, the regulatory pressure is unlikely to ease in the near term.
Most of the MBTB acquisition consideration was paid via convertible bonds, and the counterparties included the largest shareholder and related-party entities, leading to interpretations that new-business expansion and listing-maintenance efforts are intertwined.
MBTB's former shareholders effectively received compensation only in convertible bonds, and there are concerns that recoverability has become more uncertain as the stock price has recently traded below the conversion price. The timing and scale of MBTB's actual revenue contribution also remain unconfirmed, adding to the uncertainty.
Kespion has previously been in a state of partial capital impairment, with accumulated deficits reaching KRW 22.1 billion against paid-in capital of KRW 19.1 billion, and owners' equity shrank from KRW 23.06 billion in 2023 to KRW 13.41 billion in 2025.
Amid this, the company was disclosed in August 2026, alongside seven other KOSDAQ issuers, as at risk of management-issue designation. If formally designated, failure to restore the required thresholds within 90 trading days could lead to delisting proceedings, warranting continued monitoring.
Kespion experienced a prolonged trading halt following a roughly KRW 9.5 billion embezzlement case involving its former CEO in September 2018, and that former CEO was sentenced to prison in criminal proceedings.
Management changed after the largest shareholder shifted to ENS Investment in 2020, but the recent MBTB acquisition again involved the largest shareholder and related-party entities as counterparties, keeping market attention on the transparency of such transaction structures.
MBTB's sales were minimal at the time of acquisition, and its earnings contribution appears to have been delayed by facility investment burdens. Whether the company's stated expectation of overseas sales beginning within the year and its next-year target of KRW 10 billion will actually be achieved remains unconfirmed.
The technology and profitability gap versus the hydrocolloid patch market's leading players is also substantial, meaning it may take time for the new business to become a genuine cash-generating operation.
Investors should check whether the company is formally designated a management-issue stock following its recent at-risk disclosure. If designated, the delisting-procedure clock would begin running in earnest.
The Q3 report should be checked to see whether the operating profit and net income trend seen in Q1-Q2 2026 continues into the third quarter.
It is worth watching whether the company's stated expectation of MBTB overseas sales beginning within the year is confirmed through actual disclosures or reported results.
Progress on zinc-air battery patent registration and defense-industry entry procedures should be tracked to gauge concrete advancement of defense diversification.
This is when the KOSDAQ market-cap delisting threshold is set to rise further to KRW 30 billion, requiring a fresh check on whether the tightened requirement is met.
Kespion showed signs of a shift in earnings direction, with both operating profit and net income turning positive for two consecutive quarters in Q1 and Q2 2026.
However, summing the most recent four quarters still shows a net loss due to the large Q4 2025 shortfall, and whether this profitable trend continues needs confirmation from upcoming quarterly results.
The structure of heavy reliance on large customers remains intact, with about 96% of revenue concentrated in mobile antenna products, and while the MBTB acquisition and merger along with defense diversification are underway to mitigate this, their actual revenue contribution remains limited so far.
Partial capital impairment, shrinking equity, and the August 2026 disclosure flagging risk of management-issue stock designation show that structural risks around listing maintenance remain very much alive.
Market views are also mixed regarding the related-party transaction structure and convertible-bond-based acquisition method behind the new business.
Overall, this is a phase where early signs of earnings recovery, business diversification efforts, and financial and listing-maintenance risks coexist, with upcoming quarterly results and the outcome of listing-requirement responses likely to be the key points to watch.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.